A secondary mutation in BRAF confers resistance to RAF inhibition in a BRAF V600E-mutant brain tumor
收藏NIAID Data Ecosystem2026-05-26 收录
官方服务：
资源简介：
A single adolescent patient with a BRAF V600E mutated brain tumor was treated with dabrafenib and had a complete response, followed by progression. The pre-treatment and post-progression tumors were both sequenced in order to identify potential drivers of resistance.
创建时间：
2018-11-08
